Dosing of NVG-291, NervGen Pharma’s investigational therapy for multiple sclerosis (MS) and other nervous system diseases, was completed in the third and final group of healthy postmenopausal women in a Phase 1 clinical trial. “Completing the dosing of the final [group] of postmenopausal females in the MAD [multiple…

NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an investigational treatment for multiple sclerosis (MS) and other nervous system diseases. A safety review committee cleared the…

NVG-291, an experimental therapy designed to promote nervous system repair, has so far been well tolerated in an ongoing Phase 1 study with healthy volunteers. “The Phase 1 study is progressing very well, and we are encouraged by the data we are seeing so far,” Daniel Mikol, MD, PhD, chief…

MS Doctors, Nurses in UK Struggle With Marking Transition to SPMS The issue highlighted in this story isn’t just a problem in the U.K.; it’s a universal MS problem. People with MS often ask how they will know when their illness has transitioned from relapsing to progressive. I respond…

NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion of its Phase 1 clinical trial of NVG-291, a therapeutic candidate for multiple sclerosis (MS). The trial’s Safety Review Committee approved the second group after seeing promising safety data…

NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions, in a Phase 1 trial with healthy volunteers. This multiple ascending dose (MAD) part, in which participants will receive increasing doses of NVG-291…

Nerve Repair Therapy NVG-291 Safe, Well-tolerated in Healthy People This experimental therapy has a long way to go before it becomes reality. But it’s encouraging that this first step found NVG-291’s side effects to be mild and short-lasting. NVG-291 is designed to promote remyelination by modulating an enzyme called…

A single dose of NVG-291, a potential nerve repair therapy for multiple sclerosis (MS), was safe and well-tolerated among healthy volunteers in a Phase 1 safety trial, and was found to have favorable pharmacological properties, new data show. Given the positive results thus far, a safety committee supervising…

A partnership will allow NervGen to use Imeka‘s proprietary biomarker imaging technology to precisely measure changes in the brain and spinal cord in its upcoming clinical trials, including a study of NVG-291 in people with multiple sclerosis (MS) NervGen plans to initiate Phase 1b/2 trials into its lead candidate for neural…

NervGen Pharma announced that its Phase 1 clinical trial evaluating the safety and pharmacological properties of NVG-291 — its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions — in healthy volunteers is going according to plan, with early top-line data expected later this year. “The…

NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who will work with the company as it prepares to start a Phase 2 clinical trial next year testing its lead compound, NVG-291, in people with MS. “We are honored to…

NervGen Pharma announced plans to open clinical trials evaluating the potential of its lead candidate NVG-291 to treat multiple sclerosis (MS) and spinal cord injury. NVG-291 is an investigational peptide that has shown an ability to stimulate nerve regeneration following an injury in several animal models of disease.

A new study demonstrates that intracellular sigma peptide (ISP) can promote remyelination in a mouse model of multiple sclerosis (MS). Importantly, this study was independent of NervGen, a pharmaceutical company that is developing an ISP-like compound — NVG-291 — for the treatment of nerve injury and MS. The study,…

NervGen wants to advance the development of NVG-291, its lead investigational therapy for spinal cord damage, as a potential remyelination treatment for multiple sclerosis (MS), the company announced. Following preclinical data showing that NVG-291 promotes myelin repair and regeneration of damaged nerves in animal models of…